Hologic (NASDAQ:HOLX)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research report issued on Tuesday. They currently have a $48.00 price objective on the medical equipment provider’s stock, up from their previous price objective of $46.00. Needham & Company LLC’s target price would indicate a potential upside of 15.83% from the company’s previous close.

Several other research firms also recently issued reports on HOLX. Piper Jaffray Companies reissued a “buy” rating and issued a $48.00 target price on shares of Hologic in a research report on Thursday, November 9th. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Barclays reissued an “equal weight” rating and issued a $51.00 target price (down from $53.00) on shares of Hologic in a research report on Wednesday, August 9th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $45.00 target price (down from $50.00) on shares of Hologic in a research report on Wednesday, August 9th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $45.00 target price (down from $48.00) on shares of Hologic in a research report on Monday, October 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $47.38.

Shares of Hologic (HOLX) traded down $0.45 during mid-day trading on Tuesday, hitting $41.44. The stock had a trading volume of 3,069,100 shares, compared to its average volume of 2,768,521. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. Hologic has a 1-year low of $35.76 and a 1-year high of $46.80. The firm has a market capitalization of $11,548.39, a P/E ratio of 20.74, a PEG ratio of 2.03 and a beta of 0.95.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. During the same period in the prior year, the firm earned $0.52 EPS. The firm’s revenue was up 10.5% on a year-over-year basis. sell-side analysts forecast that Hologic will post 2.12 earnings per share for the current year.

In other Hologic news, Director Elaine Ullian sold 9,282 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Lawrence M. Levy sold 9,596 shares of the stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. Insiders have sold a total of 28,833 shares of company stock worth $1,107,270 over the last ninety days. 0.79% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Hall Laurie J Trustee boosted its stake in shares of Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares in the last quarter. Commonwealth Bank of Australia boosted its stake in shares of Hologic by 31.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 600 shares in the last quarter. Grove Bank & Trust boosted its stake in shares of Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 1,535 shares in the last quarter. National Asset Management Inc. purchased a new stake in shares of Hologic during the 2nd quarter worth about $203,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Hologic during the 2nd quarter worth about $213,000. 98.09% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Hologic (HOLX) Rating Reiterated by Needham & Company LLC” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/12/07/hologic-holx-rating-reiterated-by-needham-company-llc.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.